College Stock: Penny Stock News

The Dean’s List for Monday 4/27/09 only contains penny stocks that may outbreak breakout due to the Swine Flu epidemic. One of The Dean’s top students is an expert in the field of Pharmacy and together we’ve developed a list of 12 potential Swine Flu plays. Our segmentation strategy was to focus on respiratory-related biotech stocks with existing momentum. It’s a pure gamble which of these stocks will catch ‘Swine Mania’ but the upside potential can be astronomical.

NVAX uses a virus-like particle platform technology for infectious diseases including multiple strains of influenza, H5N1, shingles and Respiratory Syncytial Virus.

ADLS has a leading candidate called Cethromycin, a novel once-a-day oral antibiotic under review by the FDA for the treatment of mild-to-moderate community acquired pnemonia. It’s also completed Phase III clinical trials for the treatment of respiratory tract infections.

BCRX engages in the design, optimization, and development of novel drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases.

GNVC is developing a product called TherAtoh, a potential vaccination for respiratory syncytial virus, HSV-2, malaria, HIV and foot-and-mouth disease.

DVAX products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases.

HEB develops multiple products for the treatment of West Nile Virus, SARS, genital wards and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome.

HGSI development pipeline includes drugs to treat inhalation anthrax, hepatitis C and lupus.

IMM programs include hepatitis C virus, fungal diseases, and multi-drug resistant strains of bacterial infections.

INHX develops anti-infective products to treat serious infections including shingles, chicken pox and herpes.

INSM engages in the development of recombinant protein drugs. Their IPLEX product is a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions.

SVA engages in the sale of vaccines that protect against human infectious diseases primarily in China. Their Anflu drug provides a split virus influenza vaccine.

VICL develops products based on its DNA delivery technologies for the prevention and treatment of diseases including H5N1 pandemic influenza virus and cytomegalovirus.

MCET has a $1.4M market cap and is trading at $0.01. According to the company’s website, their MCT-465 drug candidate is a Toll-like Receptor (TLR) agonist, and is indicated as prospective therapy for treatment of virus infections including influenza A H1N1 and the “avian flu” virus.

HALO has a treatment called Gammagard. It’s a sterilized solution made from human plasma that contains the antibodies to help your body protect itself against infection from various diseases. A $30 billion company, Baxter International (BAX), has partnered with HALO for the distribution of Gammagard and must pay royalties for its use.

AVII is developing drugs for the treatment of rare viruses and conducts research in collaboration with the U.S. Army. The majority of this collaboration has been supported by a research contract from the Department of Defense’s Transformational Medical Technologies Iniative with the goal of developing new antiviral drugs.

XOMA is currently engaged in more than 16 active development projects across multiple therapeutic areas including autoimmune and infectious disease. The company has ongoing contracts with the National Institutes of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID) to develop monoclonal antibody products.

LWLLE is engaged in the development, manufacture, sale and distribution of disinfectant health care products including hand disinfectants, surface disinfectants, equipment disinfectants, machine disinfectants and animal disinfectants.

CBMX has also developed a semiconductor-based DNA chip, the CombiMatrix Influenza A Research Microarray, that can detect and accurately type flu strains with hemagglutinin subtypes 1 through 15 and neuraminidase subtypes 1 through 9 using a protocol that requires less than four hours start to finish. In addition to providing very high resolution information on genotype of any given flu strain, it can also provide information on novel strains of flu produced by rapid mutation or recombination between multiple strains of flu.

CERS has developed an INTERCEPT system that based on its proprietary Helinx technology for controlling biological replication.  The INTERCEPT system is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells.

CRXL focuses on the development, production and marketing of vaccines and antibodies against infectious disease worldwide. Through its portfolio of core marketed vaccines, the company has established markets in hepatitis B, respiratory and travel vaccines.

GNBT technology focuses on modulating immune responses mediated by T helper (Th) cells, a class of lymphocytes that plays a multifaceted role in the immune system, both enhancing and suppressing immune responses. The cells are essential both for obtaining a robust and long lasting response against infectious agents or cancer cells and for down regulating immune responses when the immune system becomes inappropriately stimulated, e.g. in autoimmune disease and allergy.

NNVC is developing a nanoviricided branded as FluCide(™), its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown to be effective against both common influenza subtype H1N1, as well as two different variants of bird flu subtype H5N1.

PPHM is developing a portfolio of clinical and preclinical stage monoclonal antibody-based targeted therapeutics, including bavituximab that is in a multi center Phase II clinical trial for the treatment of solid tumors and HCV infection. The company has a third Phase I clinical study to evaluate the safety, pharmacokinetics and anti-viral activity of bavituximab over a longer dosing period in patients co-infected with HCV and the human immunodeficiency virus.

QDEL offers products for infectious diseases, such as Influenza, Group A Strep, and Respiratory Syncitial Virus; and for reproductive and women’s health, including pregnancy, Chlamydia, Bacterial Vaginosis, and Bone Health. It also offers Immunoassay fecal occult blood test used to detect the presence of blood in stool specimens; and Helicobacter pylori test, a serological test to measure antibodies circulating in the blood caused by the immune response to the H. pylori bacterium.

SIGA engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases. It focuses on products for use in defense against biological warfare agents, such as smallpox and arenaviruses/hemorrhagic fevers.

GMED is a pink sheet company that uses hereditary information from DNA to improve patient outcomes. Targeted diseases include influenza, SARS, HIV, West Nile Virus and Hepatitis A, B and C.

NVLX sells nutraceutical products worldwide. The company’s Citroxin product is being tested on chicken embryos for bird flu in Thailand, as well as to eradicate the MRSA strain of staph in vitro. They also distribute  the ‘Immune Boost Bar’ designed to enhance overall immune function and help increase resistance to common viruses.

PURE develops silver dihydrogen citrate-based antimicrobials and boric acid-based pesticides that are non-toxic solutions to numerous health challenges. PURE is also developing an EPA registered hard surface disinfectant known as Axen30. It disinfects twenty times faster than other disinfectants and provides a broad spectrum of protection as a disinfectant, fungicide and viricide.

I doubt any of these stocks will actually prevent or cure Swine Flu, but history proves that epidemic plays in the stock market can breakout to absurd prices.

References:
Yahoo covers Swine Flu Stocks

PFCB closed today up 20% on quarterly earnings growth of 39% YoY. PFCB could be the #1 short squeeze on this list after today’s announcement because the stock has 7.6M shares short as of 3/31/09. I’m long for the moment and wouldn’t be surprised if it reaches $40 before reversing.

GWGI finished up 16% on 10x average volume and the stock promotion is going full throttle with BestDamnPennyStocks.com, TopBestPennyStocks.com, 24-7stockalert.net and DubaiPennyStocks.com releasing email alerts. (it’s funny how StandOutStocks.com sends out GWGI email alerts and M2.com press releases to try and take credit).

NXTH is the latest stock promotion by hototc.com and stockegg.com and the compensation appears to be coming from a 3rd party (compensated by Winning Media on behalf of York Cassing Services Ltd) so that… plus the illiquidity… will keep me on the sidelines.

HOTT is on fire and if/when this Bear Market Rally subsides it’s one of the biggest opportunities among retail shorts. But until then I’ll maintain a spectator.

OPTR completely reversed its trend back in early Nov ’07 (on quarterly earnings alone?) but they’re still losing money so it doesn’t add up to me. From what I gather, OPTR is breaking out on a short squeeze (2.5M shares short as of 3/31 or about 8% of float). If so, OPTR may have $3-$5/share upside from here.

FRPT is one stock I’m sure most of you remember well. I see very little resistance between $8 and $10 so let the trend become your best friend.

BDSI is very near its previous highs (9/2/08 & April-May ’07) and I see more potential playing this as a short. As always I’m not looking to call a top and instead I’ll wait until a top is convincingly formed until I short.

CENT is a potential short squeeze (11% of Float) but the volume has been drying up the past few days. If it moving higher ($11-$12) than expect a massive short squeeze +$20. At first glance CENT looks like a great short but there are just too many existing shorts that would provide substantial downward support upon covering.

QTM——-Short. Today was the first down day after the stock tripled in a few weeks. This is my #1 short tomorrow (if it’s below $1.20) and will look for a major crack back towards $1 range.

TRE——-Long. TRE is up 2 days in a row and should continue trending upward after that nonsensical & one-sided report by Barron’s last week. I’m going long till $4. CAR——-Short. Exactly as I pointed out yesterday…. “CAR is a real company with real revenues but it’s spiked 443% in 30 days which is unsustainable. However, I won’t short until it cracks below $1.80.”

NTWK——-Short. Red hot stock promoter StockPreacher.com is a victim of his own success… because Tim Sykes & followers are shorting it and The Dean is likely go short as well if the stock shows morning weakness. If it can break support @ $0.60 than it could quickly drop down to $0.40-$0.50.

UIS——-Short. UIS finished down 26% today and if the broader market continues trending downward tomorrow (Tuesday) than I expect UIS to follow suit until its support around $1.

SPNG——-Long. Released a promising 10-Q late afternoon which boasts some impressive growth numbers. Besides the massive dilution et al RM Enterprises I think SPNG could have a big week. (BTW I’ve already covered my short @ $0.0165 for a small gain).

DDRX released quarterly earnings after the closing bell on 4/20/09 and announced net income of $0.25/share and quarterly revenue growth of 72% YoY.

PNX just announced that they’re supposed acquisition “American Sterling Corporation” has been placed under FDIC receivership. (aka the acquisition went belly-up). This is an easy-to-borrow short with a lot of potential downside.

GWGI is a penny stock promotion by 247stockalert.net, bestdamnpennystocks.com, dubaipennystocks.com, whisperfromwallstreet.com and maybe some other groups so the promotion could take this stock higher. As always beware the gap-up and remember the importance of selling the trade.

ZLC is one I’m buying if/when it crosses $5 (the Jan 6th high) in which case it could quickly go to $5.50 or $6.

BGP is one I’d consider shorting if it gradually fades to the $1.30-$1.40 range but till then I’ll stay on the sidelines.

HZO appears to be a good short candidate as long as it doesn’t convincingly trade above the $4 high set back in late Dec ’07.

TLB is getting hammered and for very good reasons. The 52-wk low is $1.45 set on 1/21/09 and it wouldn’t shock me if TLB re-tested that low.

Below are the stocks i’m most likely to trade on Monday 4/20/09. OPMG & TRE are the most likely buys unless either gap up big….

OPMG——-Long. It’s a paid penny stock promotion led  by OTCJournal.com, hototc.com and stockegg.com. They’ve all been paid cash directly from the company and in my experiences these kind of promotions work best. I’ll look to buy early and as always… beware the big gap up! (BTW WhisperFromWallStreet.com is trying to steal these guys thunder by making it their own “big pick” but don’t be fooled… they weren’t paid on this deal). 

TRE——-Long. TRE got crushed last week due to a negative article by Barron’s Vito Rancanelli but the article was entirely one-sided and filled with half-truths. I’ll be buying early as its appeared to bottom and is now trending upward.

CHRT——-Long. Very positive joint venture agreement with IBM announced pre-market on Thursday 4/16 and there is very little resistance until $1.50ish.

CAR——-Short. CAR is a real company with real revenues…. But it’s spiked 443% in 30 days which is unsustainable. However, I won’t short until it cracks below $1.80.

DTG——-Long. If DTG can break through all its resistance and trade above $2.50 it could trigger a short squeeze and quickly move to $3-$5 range.

NVBG——-Long. It’s a $30,000 cash paid pump by TopBestPennyStocks.com. Their last 3 promotions were UTRM, EUOK & LVCA and considering the latest one jumped +200%… I’ll look for a quick scalp to the upside.

AGTI——-Long. It’s another stock promotion by hototc.com & stockegg.com. Their 3rd party source is Jak Trading Inc. who paid the duo a total $25,000 cash for the promotion. This will very likely gap up in the early A.M and its very illiquid.

CGA——-Long. I mentioned CGA in yesterday’s edition of The Dean’s List as a “technical traders dream” and I still feel the same about it.

VTG——-Long. VTG was also in yesterday’s edition of The Dean’s List. One concern is that the stock’s volume is drying up… in which case VTG could also be a good short play w/ light volume + weakness.

PRXI——-Long. Ultra bullish news today about “world renowned Titanic explorer and adventurer” Michael G. Harris offering $3/share for over 4M shares from Sellors Capitol LLC. PRXI closed today up 72% to $1.19 and IMO it could see $1.50-$2 short-term.

PZG——-Short. PZG gapped up on a paid stock promotion research report by http://www.stansberryresearch.com and I’ll reserve shares in A.M. and look to short into weakness.

RT——-SHORT. I’m breaking all the rules w/ RT since it hasn’t shown any signs of weakness (yet). I’m betting on crowd-mentality and the Great Recession on this one. My stop loss is GTC @ $6.20.

MTIZ——-LONG. MTIZ is being pumped by some of my favorite newsletters including hototc.com so it could have a big day to the upside. Sign up for their newsletter because they’ve had some big winners lately and as always… beware the early A.M. gap up.

RUTH——-LONG. RUTH had an afternoon spike and closed up 35%. All the volume came out of nowhere and IMO it’s a coordinated group of buyers trying to create a short squeeze so therefore I’m playing RUTH to the upside.

UTRM——-SHORT. UTRM is a pump courtesy of 24-7stockalerts.net and IMO the play is now to go short since 24-7 is such an effective group and contributed to a ridiculous run of +300% in 3-days.

KONA——-LONG. In my opinion KONA is another potential short-squeeze-with-wheels and I’ll most likely buy shares if it can break out above $2.05.

5 stocks i’m watching closely on today’s world-renown-patent-pending-money-making issue of The Dean’s List featuring 3 SHORT’s & 2 LONG’s……….

CLRT—–LONG. CLRT has some major momentum and seeing that its formed a base @ $2.20 I believe the play is long. If it takes out support @ $2.20 be very careful!

SNR—–SHORT. SNR is a Lebed.biz pick and seeing that (1) I haven’t gotten 1,342 emails from him tonight and (2) his 3rd party most likely unloaded shares today… i’m looking for shares to short.

DISK—–SHORT. DISK finished up 33% on Tuesday 4/7/09 due to an amended merger agreement and i’ll reserve shares to short early but wait till its in the red on the day.

IMGN—–LONG. IMGN has wheels and if it can break out above $8.04 than its next stop is +$9 in my opinion (as always).

ASGR—–SHORT. ASGR is up 50% during the past 4 weeks and the chart screams parabolic rollercoaster to the downside!

TIXC is a stock I did consulting work for back in the day (2004-2005). There was a flood of buying right before todays close… stock finished up 68% on the day. I guess somebody forgot to tell management about the newsflash: “Vegas Ghost Town As Consumers Go Bust”. I’m looking to reserve shares early and go short.

NOIZ is another overbought stock at the top of The Dean’s Short List. The stock is up from $4 to $7 during the past 2 days, and I’m looking for a meltdown back towards $5.

ALDA may look healthy (3 P/E, 0.7 P/S, near Book Value) but just like above, the stock is up from $4 to $8 during past few weeks. ALDA is my “most likely to short” stock.

KFN chart looks great for a momentum play.

BDL looks like it found support @ $3 and its another momentum play I’m following closely.

TM is still a stock that I’m buying calls on the dips. If it breaks below $65 I’ll continue gobbling up shares & 2009 Calls.

GW is profitable oil service stock, in the oil service sector, and The Dean believes the stock is headed above +$10 if they announce a record 3Q on 10/30.

RIG is another stock I’m bullish on… a 6 P/E while business is expanding is ludicrous.

BCG is already up 10% afterhours so I’ll only buy on dips, but just like RIG… its been way oversold and due for a bounce.

NOIZ closed near the intraday high on Friday and i’m looking for continued momentum throughout Monday. I’ll probably just scalp $0.25-$0.50, as NOIZ isn’t something I’d like to hold overnight.

AIM will probably make a nice short… good luck finding shares to borrow (too illiquid).

PRVT is another momentum play i’m looking to scalp a quick $0.10-$0.25 from. My intent is take a quick 15% gain, but i’m using a stop loss @ 5% below my order price, cause this stock could collapse back to $1 within minutes. If its is down intraday and looks like the momentum is dried up, I’ll look to sell it  short.